Glycosaminoglycans to Treat and Prevent Radiation-Induced Oral Mucositis
Glycosaminoglycans to Treat and Prevent Radiation-Induced Oral Mucositis
批准号:
9333339
负责人:
Won Yong Lee
金额:
$38.14万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-06-15 至 2019-08-31
关键词:
AcuteAffectAnimal ModelAnimalsAnti-Inflammatory AgentsAnti-inflammatoryApoptoticBiochemicalBlocking AntibodiesCancer PatientCathepsinsCell DeathCell Death Signaling ProcessCellsClinicalComplexCytoprotective AgentDataDeglutitionDevelopmentDiseaseDoseEnteral FeedingEnzymesEpithelial CellsEventFDA approvedFeasibility StudiesFormulationFrequenciesGastrointestinal tract structureGlycosaminoglycansHamstersHead and Neck CancerHistologicHumanInfiltrationInflammationInflammatoryInnate Immune SystemInterruptionLeadLeukocytesMeasuresMediatingMedicineModelingMolecularMolecular TargetMucositisMucous body substanceMusNarcoticsNecrosisNerve Growth FactorsOpportunistic InfectionsOralOral UlcerOral cavityOral mucous membrane structurePainPathway interactionsPatientsPhagocytosisPharmaceutical PreparationsPhasePhysiciansPreventionProcessQuality of lifeRadiationRadiation induced damageRadiation therapyRegimenResearchRoentgen RaysSafetySalivary GlandsScheduleSignal PathwaySignal TransductionSignaling MoleculeSmall Business Innovation Research GrantTLR2 geneTLR4 geneTestingThickTissuesTongueTopical applicationTransplantationUlcerXerostomiabasecancer cellcancer complicationcancer therapycell injurychemoradiationcostcytotoxiceffective therapyexperimental studyinsightirradiationneoplastic celloral mucositisoutcome forecastphase 1 studypreventprotective effectrepairedtherapy developmenttreatment grouptumor
中文摘要
摘要
英文摘要
ABSTRACT
Oral mucositis is a devastatingly painful inflammatory disease that frequently develops during cancer
therapy and affects half a million people in the US. The accompanying pain is so severe that patients often
require narcotic pain medicines. The clinical manifestations are ulcers in the mouth and gastrointestinal tract,
which are exacerbated by opportunistic infections. Many patients also suffer from dry mouth causing difficulty
in swallowing because of the decreased salivary gland function. As a result, these patients often need feeding
tubes which interrupts their cancer treatment. The financial burden to the patient is staggeringly high costing an
additional $17,000 to $40,000 for each patient. Preventing oral mucositis will therefore greatly enhance the
cancer therapy as well as the wellness of the patients. GlycoMira's lead candidate, GM-0111, is a new class of
anti-inflammatory drugs. The SBIR Phase I study results demonstrate its powerful anti-inflammatory effects in
a radiation-induced oral mucositis animal model: GM-0111 reduced tissue ulceration and inflammation in the
tongue. Histologically, tongue tissues from the GM-0111 treated group showed markedly reduced infiltration of
leukocytes with thicker mucosal layers and prevention of mucous glandular alterations compared to the tissues
from vehicle treated animals. Biochemical analyses also showed consistently lower leukocyte enzyme MPO
activity as well as reduced concentration of nerve growth factor (NGF) in GM-0111 treatment groups. In
addition, GM-0111 treatment prevented radiation-induced alterations of the salivary glands. Overall, the data
suggest that it is feasible to use GM-0111 to prevent oral mucositis. The current SBIR Phase II application
proposes to further develop GM-0111 as a viable and effective therapy for oral mucositis. The objectives are to
(1) investigate the optimal dosing regimen in a radiation-induced oral mucositis animal model, (2) determine
the optimal formulation for topical delivery of GM-0111 in the oral mucosa, (3) validate the topical GM-0111
formulation in radiation and chemoradiation-induced animal models, and (4) investigate the molecular targets
of GM-0111 to reduce oral mucositis. The results of the proposed research will lead to the delivery of a viable
and effective therapy to the patients suffering from this devastating disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Glycosaminoglycans to Treat and Prevent Radiation-Induced Oral Mucositis
-
批准号:10324268
-
项目类别:
-
资助金额:$153.09万
-
财政年份:2021
-
负责人:Won Yong Lee
-
依托单位:
Glycosaminoglycans to Treat and Prevent Radiation-Induced Oral Mucositis
-
批准号:8648538
-
项目类别:
-
资助金额:$20.0万
-
财政年份:2014
-
负责人:Won Yong Lee
-
依托单位:
Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis
-
批准号:8592461
-
项目类别:
-
资助金额:$81.48万
-
财政年份:2011
-
负责人:Won Yong Lee
-
依托单位:
Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis
-
批准号:8737875
-
项目类别:
-
资助金额:$68.52万
-
财政年份:2011
-
负责人:Won Yong Lee
-
依托单位:
Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis
-
批准号:9055050
-
项目类别:
-
资助金额:$0.7万
-
财政年份:2011
-
负责人:Won Yong Lee
-
依托单位:
海外基金